Assessment and Management of Alcohol or Benzodiazepine Withdrawal

Warning

Objectives

This treatment guideline aims to provide a concise aide in the early identification and appropriate treatment of alcohol or benzodiazepine withdrawal for those deployed on military operations.   

Scope

This guideline outlines the initial management of acute alcohol or benzodiazepine withdrawal for those deployed on military operations. It is outside of the scope of this guideline to provide direction for all situations, and in particular this relates to the availability of medications within a unit/platform/facility on Operations. Pragmatism may be required by clinicians regarding what medication they have available to them, and reach back support from a mental health professional should be considered early in the treatment pathway.

Audience

Mental Health Assessment and Initial InterventionsThis guideline is intended for the use of registered healthcare professionals fulfilling a general role in a forward medical locations or in an emergency department on deployed operations. These are not SOPs/ TTPs for deployed Mental Health (MH) clinicians and do not replace the need for deployed MH support.

Initial Assessment & Management

All personnel have the potential to display behaviour out-of-character, act erratically, or place themselves or others at risk of harm. This potential is increased on operations and should particularly be considered in psychiatric patients/ those experiencing acute symptoms of mental ill-health. Assess risk to you, those around you, and the patient ensuring an environment which is calm and without easy access to potential weapons (i.e. sharps). Routine MTF sanitisation would usually include removal of a patient’s weapon system. This should be checked, and consideration given to other potential weapons and the need for search of the patient to ensure safety. 

ACUTE ALCOHOL WITHDRAWAL

Assessment and identification

Early identification and assessment is essential to ensure appropriate management and prevent chronic sequalae for the patient. Usual symptoms, and their timing of onset, are detailed in Table 1, with more severe symptoms and their management covered later in this guidance. 

In addition to a comprehensive mental health assessment (CGO: Mental health assessment and initial interventions), patients will benefit from a more detailed alcohol history, which is shown below in accordion content. This may not be appropriate on operations due to time and privacy constraints, however, if possible, it provides very useful information for treatment and recovery (both acutely and in the longer term).

Physical health assessment is integral to the care of the patient. Regular (minimum every 4 hours) physical observations should be conducted. In addition, the physical signs of alcohol withdrawal should be scored every 4 hours using the CIWA-Ar scale, shown below. This scale indicates the severity of alcohol withdrawal and therefore guides the acute treatment. 

Table 1: Mild symptoms of alcohol withdrawal

Symptoms

Usual timing of onset after the last drink

Other information

Agitation/anxiety/irritability

Tremor of hands, tongue, eyelids

Sweating

Nausea/vomiting/diarrhoea

Fever

Tachycardia

Systolic hypertension

General malaise

 

Onset at 3–12 hours

Peak at 24–48 hours

Duration up to 14 days

 

 

 

 

 

 

Symptoms are non-specific

Absence does not exclude withdrawal

May commence before blood alcohol levels reach zero

 

 

 

 

 

 

Initial management and escalation

Significant supplies of benzodiazepines and thiamine are required to treat alcohol withdrawal. Benzodiazepines provide symptomatic relief from symptoms and aim to prevent seizures (and other complications), whilst Thiamine aims to prevent permanent neurological damage (Korsakoff syndrome). Therefore, early aeromed evacuation (or transfer to a Role 3/4 facility) is usually required to avoid complications and manage potentially life-threatening deterioration. If the operational situation does not allow for aeromed evacuation, prioritise reach back mental health professional support. 

Benzodiazepine and thiamine prescribing regimens are detailed within accordion content.

Management of severe symptoms

Generalised seizures. Severe alcohol withdrawal can lead to generalised seizures, which typically occur 12 to 18 hours after the last drink. Notably, these seizures may begin even before blood alcohol levels have completely reached zero. If this occurs, immediate stabilisation (using an ABC resuscitation approach) should be used. Evidence demonstrates that long-acting benzodiazepines preparations such as diazepam, significantly reduced seizures. 

 

Delirium tremens (DT), a severe complication of alcohol withdrawal, typically manifests 3 to 4 days (72–96 hours) after the last drink and develops in 3–5% of those admitted to the hospital for alcohol withdrawal. 

Symptoms include: 

  • clouding of consciousness or confusion, 
  • vivid visual and tactile hallucinations, 
  • marked tremor
  • autonomic hyperactivity (such as tachycardia, hypertension, sweating, and fever). 
  • Other features may include paranoid delusions, agitation, and insomnia, with prodromal symptoms like night-time insomnia, restlessness, fear, and confusion. 

Risk factors for DT include severe alcohol dependence, self-detoxification without medical input, multiple prior admissions for alcohol withdrawal, concurrent medical illness, a history of DT or alcohol withdrawal seizures, low potassium or magnesium levels, thiamine deficiency, and inadequately treated withdrawal. 

DT is a medical emergency, with a mortality rate of 10–20% if untreated. Prompt recognition is crucial, as the treatment for DT differs from delirium due to other causes. Larger doses of benzodiazepines are often needed, and antipsychotics must be used with caution. Management ideally requires a high-dependency setting.

 

ACUTE BENZODIAZEPINE WITHDRAWAL

Assessment and identification

Symptoms of benzodiazepine withdrawal are shown in Table 2. Symptoms can occur within a wide timeframe from last benzodiazepine dose (due to variable half-lives), are non-specific, and can vary wildly from patient to patient. The risk of withdrawal symptoms increases with longer use, higher dosage, and concurrent alcohol or other drug dependence. 

A full mental health assessment (CGO: Mental health assessment and initial interventions,) should be completed, and in addition the detailed alcohol history (Accordion content) can be of benefit. 

Physical assessment should also be undertaken, with minimum 4 hourly physical observations conducted. Supportive management (fluids or antiemetic medication) may be required.

Table 2: Symptoms of benzodiazepine withdrawal 

Physical

Psychological

Stiffness

Weakness

GI disturbance

Paraesthesia

Perspiration

Headache

Tremor

Loss of appetite

Nausea

Palpitations

Visual disturbance

Tinnitus

Seizures

Anxiety

Panic attacks

Insomnia

Nightmares

Depersonalisation

Decreased memory and concentration

Delusions and hallucinations

Depression

 

 

 

 

 

Management

The principle of management is to convert the patient to an equivalent dose of diazepam from whatever benzodiazepine they have been taking, and then gradually reduce this diazepam dose. 

It is important to note that patients may be taking multiple types of benzodiazepine, and that without good rapport and encouragement they may under-report their dosing. Therefore good monitoring of withdrawal symptoms and physical health/observations should occur. 

As with the management of acute alcohol withdrawal, early aeromed evacuation or transfer to a Role 3/4 facility is likely to be necessary due to the need for large quantities of diazepam. If this is not possible then early reach back from a mental health professional should be sought where possible. 

The following stepwise discontinuation protocol, adapted from the BNF, can be used as a guide. The reduction schedule may be tailored to the individual patient as required:

          1.       Step 1: Transfer the patient onto an equivalent daily dose of diazepam,     ideally taken as a single dose at night. See Table 3. 

Table 3: Diazepam equivalent doses. 

Approximate equivalent doses, diazepam 5 mg

Alprazolam

250 micrograms

Clobazam

10 mg

Clonazepam

250 micrograms

Flurazepam

7.5–15 mg

Chlordiazepoxide

12.5 mg

Loprazolam

0.5–1 mg

Lorazepam

500 micrograms

Lormetazepam

0.5–1 mg

Nitrazepam

5 mg

Oxazepam

10 mg

Temazepam

10 mg

  1.        Step 2: Reduce diazepam dose in fortnightly steps of 2mg-2.5mg; if withdrawal symptoms occur, maintain this dose until symptoms improve.
  2.        Step 3: Reduce the dose further, if necessary, in smaller fortnightly steps; it is better to reduce too slowly than too quickly
  3.        Step 4: Stop completely; time needed for withdrawal can vary from about 4 weeks (or less) to a year or more.

Alcohol History Aide Memoire

Drinking pattern

  • Age when patient had their first alcoholic drink
  • Age when patient first began to drink regularly
  • Description of a typical day’s alcohol consumption:
    • Time of first drink?
    • Where do they consume their alcoholic drinks?
    • What type of alcohol is consumed?
    • How is their alcohol consumption spread through the day?
  • What is their weekly alcohol consumption?
  • Where did they last consume an alcoholic drink?
  • Has there been any accidents related to drinking alcohol?

 

Signs of Dependence

  • Salience – does the need for alcohol have overarching importance over the patient’s life?
  • Tolerance – does the patient need to consume more alcohol to get the same effect?
  • Withdrawals – does the patient have withdrawals in the morning or when unable to obtain alcohol?
    • Withdrawal symptoms include nausea, tremor, anxiety, agitation, sweats, orientation disturbances, tactile disturbances, auditory disturbances, visual disturbances and headache
  • Narrowing of drinking repertoire
  • Impaired control
  • Compulsion to drink
  • Continued use despite evidence of harm

 

Impact of alcohol

  • Has the patient’s alcohol consumption had a negative impact on their work?
  • Has the patient’s alcohol consumption had a negative impact on their family life?
  • Has the patient been in trouble with the police secondary to their alcohol consumption?
  • Is the patient in financial difficulties secondary to their alcohol consumption?

 

Previous treatment attempts

  • Has the patient had any previous detoxes? If so, were they in-patient or community detoxes?
  • How long is the patient’s greatest period of abstinence?
  • What was helpful during any periods of abstinence or periods of controlled/moderate alcohol consumption?
  • What other treatment or support has the patient received for their alcohol difficulties?

 

Patient goals

  • If anything, what does the patient want to change?
  • Have work colleagues, friends or family members made comments suggesting that their alcohol consumption should be reduced?
  • Does the patient want any support for their potential alcohol disorder?
  • Does the patient have a supportive social network?
  • Where is the patient in the change cycle?

 

Substances and gambling

  • Does the patient use any illicit substances or is addicted to any other substance?
  • Does the patient report any problems with gambling?
  • Does the patient smoke?

 

Physical health

  • Is there any evidence of cognitive problems?
  • Are there any signs of withdrawal?
  • Are they eating adequately?
  • Has there been any recent vomiting or other gastrointestinal symptoms?
  • Has the patient had a history of physical or head injuries secondary to being intoxicated?

 

 

 

CIWA -AR Scale

  1. Nausea and Vomiting
  • 0: None
  • 1: Mild nausea, no vomiting
  • 2–4: Intermittent nausea with dry heaves
  • 5–7: Constant nausea, frequent dry heaves, or vomiting

 

  1. Tremor
  • 0: No tremor
  • 1: Not visible but can be felt
  • 2–4: Moderate tremor visible with arms extended
  • 5–7: Severe tremor even with arms at rest

 

  1. Paroxysmal Sweats
  • 0: No sweat
  • 1: Barely perceptible moisture on palms
  • 2–4: Moderate sweating, damp on clothes
  • 5–7: Drenched sweat

 

  1. Anxiety
  • 0: No anxiety, at ease
  • 1: Mild anxiousness
  • 2–4: Moderate anxiety, evident fear or worry
  • 5–7: Severe, acute panic

 

  1. Agitation
  • 0: Normal activity
  • 1: Somewhat more than normal
  • 2–4: Moderately fidgety and restless
  • 5–7: Pacing, unable to stay seated

 

  1. Tactile Disturbances
  • 0: None
  • 1: Mild itch or pins and needles
  • 2–4: Intermittent skin crawling or burning
  • 5–7: Severe, constant sensations

 

  1. Auditory Disturbances
  • 0: None
  • 1: Mild sensitivity to sound
  • 2–4: Moderate harshness or auditory illusions
  • 5–7: Severe hallucinations

 

  1. Visual Disturbances
  • 0: None
  • 1: Mild sensitivity to light
  • 2–4: Moderate illusions or flashes of light
  • 5–7: Severe hallucinations

 

  1. Headache or Fullness in Head
  • 0: None
  • 1: Mild, barely noticeable
  • 2–4: Moderate, annoying
  • 5–7: Severe, incapacitating

 

  1. Orientation and Clouding of Sensorium
  • 0: Fully oriented
  • 1: Uncertain about date
  • 2: Disoriented about place or person intermittently
  • 3–4: Disoriented consistently

 

Scoring Interpretation:

Score

Severity

Management

 

 

 

 

Supportive/medical care

Benzodiazepine

Thiamine supplementation

 ≤ 10

Mild

Moderate-to-high-level supportive care, little, if any medical care required

Little to none required

 

Oral likely to be sufficient if patient is well nourished

 ≤ 15

Moderate

Moderate-to-high-level supportive care, little medical care required

Little to none required

 

Pabrinex should be offered if the patient is malnourished followed by oral supplementation

> 15

Severe

High-level supportive care plus medical monitoring

Symptomatic and substitution treatment required

Pabrinex should be offered followed by oral supplementation

 

 

Prescription Regimens for Alcohol Withdrawal/Detoxification

The majority of UK guidelines are based on Chlordiazepoxide regimen however due to this not being included on the module list at Role 1 and 2, Diazepam regimen has also been included below.

Regimens provided for severe and moderate symptoms are an initial guide and should be adjusted to match clinical presentation; dose should be reviewed if a patient is becoming excessively drowsy.

Lorazepam should be used in patients with evidence of liver disease. Engage with reach back mental health professional in such circumstances.  

Severe symptoms (CIAW-AR Scale) (high risk) regime

Chlordiazepoxide Regimen

- Day 1: 30 mg QDS

- Day 2: 20 mg QDS

- Day 3: 15 mg QDS

- Day 4: 10 mg QDS

- Day 5: 10mg, 5mg, 5mg, 10mg

- Day 6: 5mg QDS

- Day 7: 5mg BD

---OR---

Diazepam Regimen

- Day 1: 20 mg QDS

- Day 2: 15 mg QDS

- Day 3: 10 mg QDS

- Day 4:  5mg QDS

- Day 5 and 6: 5mg BD

--- AND ---

200-300mg Thiamine IV OD for 3 to 5 days *OR* 1 pair Pabrinex IM for 3 to 5 days.

Then: Thiamine 100mg po TDS for at least 6 weeks post detox.

 

Thiamine IV administration – Dilute the solution with glucose 5% (preferred diluent) or sodium chloride 0.9%. Suggested dilution volume 50-100ml. Give over 30 minutes using an infusion pump. Flush with sodium chloride 0.9% following administration. Thiamine has a low pH and may cause venous irritation and tissue damage in cases of extravasation. If a central venous access device is unavailable, administer via large peripheral vein monitoring insertion site closely using a phlebitis scoring tool. Re-site cannula at first signs of inflammation.

Pabrinex IM administration – Administer via deep IM. The gluteus medius or ventrogluteal site is preferred. IM injection cannot be administered in volumes larger than 5mls, but the preferred volume is no larger than 4mls. Consider rotating site and using multiple injections for larger volumes.

 

Moderate symptoms (CIWA-AR Scale) (low risk) regime

Chlordiazepoxide Regimen

- Day 1: 20 mg QDS

- Day 2: 15 mg QDS

- Day 3: 10 mg QDS

- Day 4: 5 mg QDS

- Day 5 and 6: 5mg BD

---OR---

Diazepam Regimen

- Day 1: 10mg QDS

- Day 2: 10mg QDS

- Day 3:  5mg QDS

- Day 4:  5mg QDS

- Day 5 and 6: 5mg BD

--- AND ---

Thiamine 100mg PO TDS for at least 6 weeks post detoxification.

 

 

Last reviewed: 07/11/2026

Next review date: 07/11/2027